Immune checkpoint therapy—current perspectives and future directions

P Sharma, S Goswami, D Raychaudhuri, BA Siddiqui… - Cell, 2023 - cell.com
Immune checkpoint therapy (ICT) has dramatically altered clinical outcomes for cancer
patients and conferred durable clinical benefits, including cure in a subset of patients …

Gut microbiota in colorectal cancer development and therapy

CC Wong, J Yu - Nature Reviews Clinical Oncology, 2023 - nature.com
Colorectal cancer (CRC) is one of the commonest cancers globally. A unique aspect of CRC
is its intimate association with the gut microbiota, which forms an essential part of the tumour …

[HTML][HTML] Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment

MJ Bender, AC McPherson, CM Phelps, SP Pandey… - Cell, 2023 - cell.com
The use of probiotics by cancer patients is increasing, including among those undergoing
immune checkpoint inhibitor (ICI) treatment. Here, we elucidate a critical microbial-host …

Lung microbiome: new insights into the pathogenesis of respiratory diseases

R Li, J Li, X Zhou - Signal transduction and targeted therapy, 2024 - nature.com
The lungs were long thought to be sterile until technical advances uncovered the presence
of the lung microbial community. The microbiome of healthy lungs is mainly derived from the …

Causal relationship between gut microbiota and cancers: a two-sample Mendelian randomisation study

Y Long, L Tang, Y Zhou, S Zhao, H Zhu - BMC medicine, 2023 - Springer
Background Evidence from observational studies and clinical trials suggests that the gut
microbiota is associated with cancer. However, the causal association between gut …

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

M Yi, X Zheng, M Niu, S Zhu, H Ge, K Wu - Molecular cancer, 2022 - Springer
Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

Resistance mechanisms to anti-PD cancer immunotherapy

MD Vesely, T Zhang, L Chen - Annual review of immunology, 2022 - annualreviews.org
The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …